Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging

Olivieri, Fabiola; Spazzafumo, Liana; Santini, Gabriele; Lazzarini, Raffaella; Albertini, Maria Cristina; Rippo, Maria Rita; Galeazzi, Roberta; Abbatecola, Angela Marie; Marcheselli, Fiorella; Monti, Daniela; Ostan, Rita; Cevenini, Elisa; Antonicelli, Roberto; Franceschi, Claudio; Procopio, Antonio Domenico

doi:10.1016/j.mad.2012.09.004

Cited by 211 publications

(167 citation statements)

References 75 publications

Supporting

Mentioning

151

Contrasting

Order By: Relevance

“…Similarly, recent data indicated that miR-21, released by cancer cells, may induce the secretion of pro-inflammatory cytokines (such as TNF and IL6), suggesting a direct link between miR-21 expression levels and inflammatory response. As a result, miR-21 is directly associated to CRP levels as well [31]. These findings may open the door to future studies evaluating the role of microRNAs (miRNAs) as biomarkers of inflammation and prognosis in the setting of LC patients [32].…”

Section: Discussionmentioning

confidence: 96%

Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer

Pastorino

Morelli

Leuzzi

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

Background: Higher blood levels of C-reactive protein (CRP) have been associated with shorter survival in patients with cardiovascular, chronic obstructive pulmonary disease and cancer. We investigated the impact of baseline and postoperative CRP levels on survival of patients with operable lung cancer (LC). Patients and methods: CRP values at baseline (CRP 0 ) and 3 days after surgery (CRP 3 ) were measured in a consecutive series of 1750 LC patients who underwent complete resection between 2003 and 2015. Patients were classified as having 0 (N Z 593), 1 (N Z 658) or 2 (N Z 553) risk factors: CRP 0 and/or CRP 3 values above the respective median value. The effect of higher CRP was evaluated by KaplaneMeier mortality curves and adjusted hazard ratio (HR) with 95% confidence interval (CI), by fitting Cox proportional hazards models. Results: Cumulative proportions of 5-year survival were 67% for 0 risk factors, 58% for 1 risk factor and 41% for 2 risk factors (P < 0.0001). The overall 5-year mortality risk was significantly higher in patients with 1 risk factor (adjusted hazard ratio [aHR] 1.43 [95% CI 1.14e1.79]), or 2 risk factors (aHR 2.49 [95% CI 1.99e3.11]). A significant impact on survival was observed in each tumour-node-metastasis stage group, and in the subset of non-smokers. Postoperative 30-

show abstract

Section: Discussionmentioning

confidence: 96%

Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer

Pastorino

Morelli

Leuzzi

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Plasma (circulating) miRNAs have been proposed as biomarkers for several diseases and ageing [9][10]. Our aim was to characterize the plasma miRNA profile in PD patients and healthy controls, to determine its usefulness as biomarkers for PD.…”

Section: Dear Sirsmentioning

confidence: 99%

Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls

et al. 2013

View full text Add to dashboard Cite

Plasma microRNAs (miRNAs) are promising biomarkers for several diseases. Our aim was to define the miRNA profile in plasma from Parkinson´s disease (PD) patients and healthy controls. We performed TaqMan low density arrays (TLDAs) in pools of patients and controls. Seven miRNAs differently expressed between the two groups were individually assayed in a total of 31 PD patients and 25 controls. remained significantly increased in patients vs. controls. A bioinformatic analysis predicted that this miRNA could be involved in the regulation of genes related with PD and brain function (axon guidance, MPK signaling pathway or insulin signaling pathway). We concluded that miR-331-5p could be a candidate plasma miRNA to be studied in PD related pathways. Plasma (circulating) miRNAs have been proposed as biomarkers for several diseases and ageing [9-10]. Our aim was to characterize the plasma miRNA profile in PD patients and healthy controls, to determine its usefulness as biomarkers for PD. The study was approved by the Ethical Committee of Hospital Universitario Central de Asturias (HUCA) and all the participants signed an informed consent. The study cohort consisted on sex and age matched healthy controls (n=25; mean age 67.6; 52% males) and patients (n=31; mean age 63.9; 55% males) who fulfilled the PD-clinical diagnosis criteria [11]. None of the patients was receiving drugs for PD-treatment or had a diagnosis of cardiovascular or tumor disease.

show abstract

“…MiR-21 is known as an oncomiR due to its overexpression in several human tumours, for instance in breast cancer (Kumar, et al 2013) and it has also been suggested as a biomarker of "inflamm-aging" (Olivieri, et al 2012b). According to Olivieri et al (2012b), plasma miR-21 levels showed age-related differences as well as variations between patients in relation to age-associated conditions, such as cardiovascular disease, and their agematched controls. Interestingly, miR-21 has been shown to regulate FasL expression (Sayed, et al 2010).…”

Section: Introductionmentioning

confidence: 99%

Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy – A study with monozygotic twin pairs

Kangas

Pöllänen

Rippo

et al. 2014

Mechanisms of Ageing and Development

Self Cite

View full text Add to dashboard Cite

Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging

Cited by 211 publications

References 75 publications

Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer

Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer

Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls

Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy – A study with monozygotic twin pairs

Contact Info

Product

Resources

About